Agreement to push Antibody Development forward

International Biotech Genmab has been granted a licencing agreement to progress Scancell’s investigational anti-glycan monoclonal antibody into multiple novel therapeutic products.

The agreement grants Genmab the exclusive right to develop and commercialise the humanised antibody for any and all potential disease areas, excluding cell therapy applications. Scancell will be eligible to receive an upfront payment as well as potential milestone payments, of up to $208 million for each product developed and commercialised, up to a maximum of $624 million, if Genmab develops and commercialises products across all defined modalities. It will also receive low single  digit  royalties on net sales of products.

Developed on the company’s anti-cancer GlyMab® platform the anti-glycan monoclonal antibody is one of five currently in Scancell’s antibody portfolio, providing a rich reservoir of potential products for its own in house clinical development and also for further deals.

Prof Lindy Durrant, Chief Executive Officer, Scancell, commented: “This license agreement with Genmab provides strong validation for our proprietary GlyMab® platform and our ability to utilise this technology to support the creation of novel, differentiated antibody products. Genmab is a leader in the field of antibody therapies for cancer and we are very pleased to be working with them to progress this novel antibody product through clinical development and commercialisation.”

More information online